- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05057364
Heart Smart: A Virtual Self-Management Program for Homebound People With Heart Failure
7. mars 2022 oppdatert av: Sara Frye, MS OTR/L ATP, University of Pennsylvania
The purpose of this capstone project is to pilot Heart Smart, a virtual group program to improve self-efficacy for self-management skills for homebound people with heart failure.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The purpose of this capstone project is to pilot Heart Smart, a virtual group program to improve self-efficacy for self-management skills for homebound people with heart failure.
Heart Smart will provide synchronous virtual group education to homebound people with heart failure receiving services from Penn Medicine at Home.
The primary clinical goal is to improve self-efficacy for heart failure self-management and improve their knowledge of heart failure self-management strategies.
Secondary outcomes will explore the feasibility of the program by exploring technology, adherence and satisfaction with the program.
Studietype
Intervensjonell
Registrering (Faktiske)
5
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forente stater, 19004
- Penn Medicine at Home
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Diagnosis of heart failure
- Receiving home health care from Penn Medicine at Home at time of screening.
- Technology capabilities to participate in the program (laptop or tablet with a camera, internet access).
- Able to read and write in English.
- Cognitive ability to participate in the program if the participant is able to score12/15 on the Montreal Cognitive Assessment (MoCA) 5 Minute Phone Test.
Exclusion Criteria:
- Hearing impairment that impacts communication.
- Previous experience receiving occupational therapy services from the principal investigator.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Heart Smart Group
Receives Heart Smart Intervention
|
The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Self-Efficacy Measure for Chronic Disease (SEMCD)
Tidsramme: At first and final sessions (weeks 1 and 6)
|
This self-report scale has 6 items which are each rated on a scale of 1 (not at all confident) to 10 (totally confident).
The score for the scale is the mean of the scores for the six items.
Possible scores are 1-10 with higher scores indicating higher self-efficacy.
This scale is an appropriate outcome measure for a heart failure self-management group because it was designed to measure self-efficacy in people with chronic conditions such as heart failure and has undergone psychometric evaluation.
This scale is free to use without permission.
Administration takes less than 10 minutes.
|
At first and final sessions (weeks 1 and 6)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Tidsramme: At first and final sessions (weeks 1 and 6)
|
This 23-item, Likert scale, self-report heart failure specific outcome measure.
The instrument measures six domains: physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.
This instrument is appropriate because it is designed for use for people with heart failure, will give an indication of participant heart failure severity for demographic purposes, and has a validated self-efficacy component.
This scale requires a license which has been obtained for this pilot project.
Administration takes less than 10 minutes.
Scores range from 0 to 100 with higher scores indicating higher cardiac health status.
|
At first and final sessions (weeks 1 and 6)
|
|
Change in Atlanta Heart Failure Knowledge Test V3 (AHFKT)
Tidsramme: At first and final sessions (weeks 1 and 6)
|
This 30 item multiple choice measure of heart failure self-management knowledge yields scores 0-30 which are commonly reported as a percentage (higher scores indicate more knowledge).
Content validity was established through a panel of expert heart failure nurses.
|
At first and final sessions (weeks 1 and 6)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Attendance
Tidsramme: At each weekly session for 6 weeks
|
The number of participants at each meeting will be recorded.
|
At each weekly session for 6 weeks
|
|
Minutes of training
Tidsramme: This will be recorded in the first session at week 1.
|
The number of minutes spent in the pre-training session will be recorded.
|
This will be recorded in the first session at week 1.
|
|
Participant Satisfaction
Tidsramme: At the final session on week 6
|
Participants will answer three likert scale questions.
|
At the final session on week 6
|
|
Technology failures
Tidsramme: At each weekly session for 6 weeks.
|
Total number of minutes missed per participant per session.
|
At each weekly session for 6 weeks.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Sara Frye, MS OTR/L ATP, Penn Medicine at Home Professional Development Department
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Ritter PL, Lorig K. The English and Spanish Self-Efficacy to Manage Chronic Disease Scale measures were validated using multiple studies. J Clin Epidemiol. 2014 Nov;67(11):1265-73. doi: 10.1016/j.jclinepi.2014.06.009. Epub 2014 Aug 3.
- Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000 Apr;35(5):1245-55. doi: 10.1016/s0735-1097(00)00531-3.
- Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001 Nov-Dec;4(6):256-62.
- Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003 Aug;26(1):1-7. doi: 10.1207/S15324796ABM2601_01.
- Butler J, Khan MS, Mori C, Filippatos GS, Ponikowski P, Comin-Colet J, Roubert B, Spertus JA, Anker SD. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 Jun;22(6):999-1005. doi: 10.1002/ejhf.1810. Epub 2020 Apr 2.
- Butts B, Higgins M, Dunbar S, Reilly C. The Third Time's a Charm: Psychometric Testing and Update of the Atlanta Heart Failure Knowledge Test. J Cardiovasc Nurs. 2018 Jan/Feb;33(1):13-21. doi: 10.1097/JCN.0000000000000413.
- Spertus JA, Jones PG, Kim J, Globe D. Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. Qual Life Res. 2008 Mar;17(2):291-8. doi: 10.1007/s11136-007-9302-5. Epub 2007 Dec 29.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
28. september 2021
Primær fullføring (Faktiske)
31. desember 2021
Studiet fullført (Faktiske)
31. desember 2021
Datoer for studieregistrering
Først innsendt
31. august 2021
Først innsendt som oppfylte QC-kriteriene
15. september 2021
Først lagt ut (Faktiske)
27. september 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
9. mars 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. mars 2022
Sist bekreftet
1. mars 2022
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 849646
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .